Co-Diagnostics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-46.9M | $-37.6M | $-35.3M | $-14.2M | $36.7M | $42.5M | $-6.2M | $-6.3M |
| Depreciation & Amortization | $1.1M | $1.4M | $1.2M | $1.3M | $335.4K | $138.6K | $65.9K | $50.8K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.2M | $5.4M | $8.3M | $7.5M | $5.5M | $2.7M | $1.1M | $1.3M |
| Net Cash from Operating Activities | $-29.1M | $-29.2M | $-22.1M | $6.6M | $41.1M | $28.2M | $-5.5M | $-4.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $700.0K | $748.4K | $1.4M | $1.4M | $669.5K | $774.4K | $113.2K | $41.3K |
| Business Acquisitions | — | — | — | — | $-1.2M | — | — | — |
| Net Cash from Investing Activities | $26.3M | $17.1M | $15.4M | $-58.2M | $4.1M | $-5.8M | $-435.2K | $-380.3K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $1.4M | $14.2M | — | — | — | — |
| Net Cash from Financing Activities | $11.8M | $103.9K | $-1.4M | $-14.0M | $450.4K | $19.7M | $5.9M | $1.9M |
| Net Change in Cash | $8.9M | $-12.0M | $-8.1M | $-65.6M | $45.6M | $42.1M | $-57.1K | $-2.6M |
| Free Cash Flow | $-29.8M | $-29.9M | $-23.4M | $5.1M | $40.4M | $27.4M | $-5.6M | $-4.1M |